Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion.
The objective of this study was to assess whether cimetidine affects the pharmacokinetics of sustained-release (SR) bupropion hydrochloride and the active metabolite, hydroxybupropion. This randomized, open-label, two-period crossover study was conducted in 24 healthy volunteers 18 to 45 years of age. ANOVA showed that administration of two 150 mg bupropion SR tablets with one 800 mg cimetidine tablet following an overnight fast did not change values for AUC infinity, Cmax, tmax, t1/2, and CL/F (CL/F calculated for bupropion only) for either bupropion or hydroxybupropion as compared with two 150 mg bupropion SR tablets alone. In this study, it appears that there is no effect of cimetidine on the pharmacokinetics of bupropion SR.
Kustra
R
R
Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.
Corrigan
B
B
Dunn
J
J
Duncan
B
B
Hsyu
P H
PH
D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000097:blood / Q000493:pharmacokinetics*; D016642:Bupropion / Q000097:blood / Q000493:pharmacokinetics*; D002927:Cimetidine / Q000494:pharmacology*; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005215:Fasting; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D016642:Bupropion; D002927:Cimetidine